A new market report values the sector at $97.5 billion in 2025 and expects oral and multi-pathway drugs to grow fastest as Medicare coverage starts in mid-2026.
Recap by typeshit. Full story at Yahoo Finance.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.
Forbes compares what brand-name semaglutide and tirzepatide cost against compounded GLP-1 versions.
Tirzepatide sales alone beat the total quarterly revenue of Novartis, GSK and BMS. Mounjaro rose 65% and Zepbound 59%.
HHS now lets pharmacies compound BPC-157, TB-500 and four others, but BoxingInsider notes all six remain on WADA's banned list for licensed boxers.
Politico looks at the warning signs around Health Secretary Kennedy's move to let six peptides that lack FDA approval reach the US market.
Loading…